Showing results (381-390 of 393) with videos related to
Sort By:
Pageof 40
Trials|December 8, 2025
The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapyGioia Riboni-Verri, Christopher E McMurran, Trisha Mukherjee, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 9, 2020
Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosisRuth Geraldes, Maciej Juryńczyk, Giordani Dos Passos, et al.Neurology|March 12, 2022
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple SclerosisAlberto Calvi, Ferran Prados Carrasco, Carmen Tur, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 1, 2015
DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?Steven H P van de Pavert, Nils Muhlert, Varun Sethi, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 8, 2016
Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosisMatteo Pardini, Carole H Sudre, Ferran Prados, et al.Neurology|January 7, 2011
Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRIJ J G Geurts, S D Roosendaal, M Calabrese, et al.JAMA Neurology|December 14, 2020
Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A ReviewMassimo Filippi, Paolo Preziosa, Frederik Barkhof, et al.Nature Reviews. Neurology|January 13, 2021
Mind the gap: from neurons to networks to outcomes in multiple sclerosisDeclan T Chard, Adnan A S Alahmadi, Bertrand Audoin, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 2, 2013
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease durationH Kearney, M A Rocca, P Valsasina, et al.The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.Pageof 40